Skip to content

Randomized double-blind placebo-controlled trial of Jianpijieyu Prescription in the treatment of mild to moderate depression

Treatment of heart and spleen deficiency depression effective recipe

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006729
Enrollment
Unknown
Registered
2022-10-31
Start date
2022-11-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression

Interventions

experimental group:Jianpi Jieyu Gao
control group:Jianpi Jieyu Gao simulant

Sponsors

Xiyuan Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) Meet the diagnostic criteria for DSM-V depression; 2) According to the TCM syndrome differentiation, it is the syndrome of deficiency of heart and spleen or stagnation of liver qi; 3) Men and women aged 18-65; 4) 17 items of Hamilton Depression Scale (HAMD) score =18 and =24, and one item of depression in HAMD score =2; 5) The subject agrees and signs the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Suicidal, HAMD suicide =2 points; 2) Hamilton Anxiety Scale (HAMA) score =29 for patients with severe anxiety symptoms; 3) Patients with serious or unstable heart, liver, kidney, endocrine, blood and other internal diseases; 4) Depressive episodes secondary to physical diseases; 5) Organic mental disorders, schizophrenia, bipolar disorder; 6) Depressive disorders caused by psychoactive substances (e.g., alcohol, tobacco, opioids, etc.) and non-addictive substances; 7) Have taken sedative, hypnotic, anti-depressant and other psychiatric drugs (such as risperidone and olanzapine) within one month; 8) Diabetic patients; 9) Allergic to the drug in this study; 10) Pregnant or lactating women; 11) Those who have received other clinical trials for depression in the past 3 months; 12) Those who are receiving targeted drug therapy.

Design outcomes

Primary

MeasureTime frame
HAMD-17;

Secondary

MeasureTime frame
HAMA;TCM syndrome integration;SDS;

Countries

China

Contacts

Public ContactHong Xia

Xiyuan Hospital, China Academy of Chinese Medical Sciences

970236538@qq.com13699207252

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026